Janssen Research & Development, LLC, Spring House, PA, USA
Dr Vikash Sinha, MD is a recognized and leading expert in the area of PBPK modeling currently with Global Clinical Pharmacology Dept, Janssen Research and development. In his current role as a Clinical Pharmacology leader, he is involved in early clinical development of NCEs in Immunology portfolio. He has more than 25 years of experience in Pharmaceutical Industry with about 20 years in Clinical Research and drug development.
After obtaining an MD in Clinical pharmacology, he has worked as a Senior Resident in University college of Medical Sciences Hospital, Delhi for a year. Subsequently he joined Dr. Reddy’s, India as Principal Physician - Clinical Research where he was involved in early clinical development of Cardiovascular and Anti-infective projects.
After his 5 year tenure at Dr Reddy’s, he joined Johnson and Johnson, Belgium as a Post-doc in Discovery ADME-TOX group. As a part of his post-doctoral project, he spearheaded the retrospective analysis of JNJ compounds for the prediction of human PK using empirical and physiologically based approaches. After joining Clinical Pharmacology group in 2008, Vikash led the cross-functional effort on PBPK training at Janssen sites in Belgium and US to establish and strengthen the PBPK modeling program at Janssen. Vikash has authored several publications and a book chapter in the area of PBPK and human PK prediction. He is routinely invited speaker at international symposia on value of PBPK modeling.